Home › Merck Provides Regulatory Update on Investigational Medicine Sugammadex Injection
 

Keywords :   


Merck Provides Regulatory Update on Investigational Medicine Sugammadex Injection

2015-03-13 21:02:00| Merck.com - Research & Development News

Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, said it was informed today that the U.S. Food and Drug Administration (FDA) has cancelled the meeting of the Anesthetic and Analgesic Drug Products Advisory Committee scheduled for March 18, 2015. The committee had planned to discuss the resubmission of the New Drug Application (NDA) for sugammadex injection, Mercks investigational medicine for the reversal of neuromuscular blockade induced by rocuronium or vecuronium. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orInvestors:Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: update medicine regulatory injection

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
30.09Eastern North Pacific Tropical Weather Outlook
30.09Tropical Depression Joyce Forecast Advisory Number 11
30.09California governor blocks landmark AI safety bill
30.09Tropical Storm Isaac Graphics
30.09Tropical Storm Isaac Forecast Discussion Number 17
30.09Tropical Storm Isaac Wind Speed Probabilities Number 17
30.09Tropical Storm Isaac Forecast Advisory Number 17
30.09Tropical Storm Isaac Public Advisory Number 17
More »